On Friday at 2:00 PM, you have the chance to watch as Linda Persson, CEO of NanoEcho, presents the Q2 2024 report. The webcast presentation is organised by G&W Fondkommission.
On Friday at 2:00 PM, you have the chance to watch as Linda Persson, CEO of NanoEcho, presents the Q2 2024 report. The webcast presentation is organised by G&W Fondkommission.
NanoEcho’s innovative method, with its high precision, aims to facilitate the differentiation between diseased and healthy tissue and at the same time determine a more precise localization of cancerous tissue. The goal is to provide a more reliable diagnosis of, for example cancer diseases, that has the potential to contribute to cost-effectiveness in the health care.
Not For Sale – For Clinical Investigation Use Only – EU Trial No.: 2024-515335-29-00
Mellan den 27 januari och 10 februari pågår teckningstiden i NanoEchos företrädesemission!